HollisterStier Allergy is pleased to announce the appointment of Kyle Ferguson as its new Chief Executive Officer (CEO), effective Jan. 22, 2024.
Kyle has over 35 years of leadership experience in building, launching and growing businesses in the pharmaceutical industry. He is joining the company from Sun Pharma, where Kyle held the position of Senior Vice President with P&L responsibilities over three businesses. While in this role, he led several efforts, including the launch and successful growth of an Immunology/Biologics branded business, while serving as a member of the Executive Leadership Team.
Previously Kyle has held global and US domestic leadership roles with Janssen Pharmaceuticals (part of Johnson & Johnson) and with Bristol-Myers Squibb. Kyle is a graduate of St. Francis Xavier University with a degree in Marketing and Management, and has attended various leadership development executive programs such as the London School of Economics.
“I’m privileged to join Jubilant HollisterStier Allergy as CEO,” Kyle said, “I’ll be working with a phenomenal team of individuals that are dedicated to their customers and the patients they serve. Together, we will drive the company’s growth and deliver impactful treatments to those in need. I hold immense respect for the company’s rich 100-year history and am honored to be the next steward of its enduring legacy.”
Under Kyle’s leadership, HollisterStier is projected toward an era of continued growth, innovation, and success.
About HollisterStier Allergy
For over 100 years, HollisterStier Allergy has led the force in the allergenic extract industry. Founded in 1921 in Spokane, Washington by Guy Hollister and Dr. Robert Stier, our rich history provides a strong foundation for our company, shaping our values, principles, and commitment to excellence. Today, we remain dedicated to innovation and serving the needs of healthcare professionals and patients in the allergy industry.
